233 related articles for article (PubMed ID: 25560982)
21. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
22. Dapagliflozin for the treatment of type 2 diabetes.
Brooks AM; Thacker SM
Ann Pharmacother; 2009 Jul; 43(7):1286-93. PubMed ID: 19584379
[TBL] [Abstract][Full Text] [Related]
23. Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin.
Grandy S; Hashemi M; Langkilde AM; Parikh S; Sjöström CD
Diabetes Obes Metab; 2014 Jul; 16(7):645-50. PubMed ID: 24443876
[TBL] [Abstract][Full Text] [Related]
24. Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders.
Shaikh S; Rizvi SM; Shakil S; Riyaz S; Biswas D; Jahan R
Biotechnol Appl Biochem; 2016; 63(1):145-50. PubMed ID: 25402624
[TBL] [Abstract][Full Text] [Related]
25. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
Rahelić D; Javor E; Lucijanić T; Skelin M
Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
[TBL] [Abstract][Full Text] [Related]
26. Dapagliflozin combination therapy in type 2 diabetes mellitus.
Yacoub T
Postgrad Med; 2016 Jan; 128(1):124-36. PubMed ID: 26571022
[TBL] [Abstract][Full Text] [Related]
27. Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes.
Nakamura Y; Nagai Y; Terashima Y; Nishine A; Ishii S; Kato H; Ohta A; Tanaka Y
Expert Opin Pharmacother; 2015; 16(17):2553-9. PubMed ID: 26479189
[TBL] [Abstract][Full Text] [Related]
28. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
Mikhail N
South Med J; 2015 Feb; 108(2):91-6. PubMed ID: 25688893
[TBL] [Abstract][Full Text] [Related]
29. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
[TBL] [Abstract][Full Text] [Related]
30. A single dose of dapagliflozin, an SGLT-2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus.
Hohendorff J; Szopa M; Skupien J; Kapusta M; Zapala B; Platek T; Mrozinska S; Parpan T; Glodzik W; Ludwig-Galezowska A; Kiec-Wilk B; Klupa T; Malecki MT
Endocrine; 2017 Aug; 57(2):272-279. PubMed ID: 28593615
[TBL] [Abstract][Full Text] [Related]
31. Dapagliflozin: BMS 512148; BMS-512148.
Drugs R D; 2010; 10(1):47-54. PubMed ID: 20509715
[TBL] [Abstract][Full Text] [Related]
32. Sodium glucose co-transporter 2 inhibitors: a novel approach to the management of type 2 diabetes mellitus.
Davis CS; Fleming JW; Warrington LE
J Am Assoc Nurse Pract; 2014 Jul; 26(7):356-63. PubMed ID: 24895099
[TBL] [Abstract][Full Text] [Related]
33. [Dapagliflozin (forxiga®) : SGLT 2 cotransporter inhibitor as glucose-lowering agent in type 2 diabetes].
Scheen AJ
Rev Med Liege; 2016 Oct; 71(10):463-469. PubMed ID: 28383856
[TBL] [Abstract][Full Text] [Related]
34. Dapagliflozin for the treatment of type 2 diabetes mellitus - an update.
Nicholson MK; Ghazal Asswad R; Wilding JP
Expert Opin Pharmacother; 2021 Dec; 22(17):2303-2310. PubMed ID: 34281456
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.
Sha S; Polidori D; Farrell K; Ghosh A; Natarajan J; Vaccaro N; Pinheiro J; Rothenberg P; Plum-Mörschel L
Diabetes Obes Metab; 2015 Feb; 17(2):188-97. PubMed ID: 25421015
[TBL] [Abstract][Full Text] [Related]
36. Dapagliflozin: glucuretic action and beyond.
Balakumar P; Sundram K; Dhanaraj SA
Pharmacol Res; 2014 Apr; 82():34-9. PubMed ID: 24705156
[TBL] [Abstract][Full Text] [Related]
37. SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.
Kilov G; Leow S; Thomas M
Aust Fam Physician; 2013 Oct; 42(10):706-10. PubMed ID: 24130972
[TBL] [Abstract][Full Text] [Related]
38. Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years.
Grandy S; Langkilde AM; Sugg JE; Parikh S; Sjöström CD
Int J Clin Pract; 2014 Apr; 68(4):486-94. PubMed ID: 24499168
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
[TBL] [Abstract][Full Text] [Related]
40. Dapagliflozin: a review on efficacy, clinical effectiveness and safety.
Paisley AN; Yadav R; Younis N; Rao-Balakrishna P; Soran H
Expert Opin Investig Drugs; 2013 Jan; 22(1):131-40. PubMed ID: 23127205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
